Adjuvant study of MK-3475 (Pembrolizumab) in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation

About this Study

The purpose of this study is to compare the good or bad effects of using MK-3475 after the removal of muscle invasive bladder cancer.

Sponsor Protocol ID:A031501 
IRB Number:2018-0191
Closed for Enrollment
Interventional
Phase 3
May 28, 2019
Eligibility Criteria
18 years old
Both Male and Female
Yes
No
No

Inclusion CriteriaNone

Exclusion CriteriaNone

Categories Click category to view its trials.
Cancer
Participating Locations
Cancer Center and Research Institute - UMMC
University Hospital - UMMC
Contact Information
Contact Name: Jennifer Barnes
Phone Number: 601-815-4540
Email: jbarnes@umc.edu
Principal Investigator:Henegan, John C, M.D.
How to participate in our Clinical Trials